With its blockbuster Trikafta set to lose patent protection within the decade, Vertex is strengthening its cystic fibrosis ...

VRTX secures EU approval for Alyftrek, a next-in-class triple combination regimen for treating people with CF aged six years and older.

Vertex Pharmaceuticals today announced that the European Commission has granted approval for Alyftrek ...

Vertex Pharmaceuticals said on Tuesday its next-generation cystic fibrosis treatment has won European Union approval for a ...

Vertex Pharmaceuticals (NasdaqGS:VRTX) recently received approval from the European Commission for ALYFTREK, enhancing its reach in European markets with new reimbursement agreements in Ireland and ...

ALYFTREK is currently licensed in the U.S., the UK and the European Union and is under regulatory review in Canada, Switzerland, Australia and New Zealand. About Vertex ...

ALYFTREK or TRIKAFTA is not recommended in patients with moderate hepatic impairment (Child-Pugh Class B). ALYFTREK should only be considered when there is a clear medical need and benefit ...

Analyst Ratings Published 06/17/2025, 11:02 AM 0 Vertex stock price target lowered to $420 on slower Alyftrek uptake VRTX 0.57% ...

ALYFTREK There are no available safety data for ALYFTREK in patients who previously discontinued or interrupted treatment with drugs containing ELX, TEZ, or IVA due to adverse reactions.

During the conference, the Company presented data from a pooled analysis across CFTR modulators, including ALYFTREK, which demonstrate that reduction in sweat chloride (SwCl), and therefore greater ...